However, like other targeted therapies, EGFR-TKIs lead to acquired resistance, and eventual tumor relapse compromises overall patient survival, highlighting the urgent need to develop new strategies for circumventing drug resistance (2, 3). The gene discussed is EGFR; the disease is neoplasm.